Markt geschlossen· · CNY · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced an H-share repurchase plan, under which the company intends to repurchase its H-shares with an aggregate amount of up to HK$1 billion. The shares so repurchased will be cancelled or held as treasury shares. Taking concrete action to respond to market concerns, this repurchase plan demonstrates management's unwavering confidence in the company's intrinsic value. The plan has come into
On August 25, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the first half of 2026 ("the Reporting Period", or 1H2026), the Company recorded revenue of RMB 20.442 billion, a year-on-year increase of 4.75%, or 7.17% at constant exchange rates. Profit attributable to shareholders of the listed company, net of non-recurring gains and losses, stood at RMB 1.144 billion, up 19.09% year-on-year. Profit growth outpaced revenue growth, reflectin
On 13 May, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) and AriBio Co., Ltd. ("AriBio"), a biopharmaceutical company focused on neurodegenerative diseases, today jointly announced the signing of an exclusive global option agreement for the development, registration, manufacturing and commercialization of AR1001, an innovative drug candidate for the treatment of Alzheimer's disease (AD).
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.